Open Access<p>CXCL13 Is A Biomarker Of Anti-Leucine-Rich Glioma-Inactivated Protein 1 Encephalitis Patients</p>
Author(s) -
Yanfu Lin,
Xue Yang,
Jima Lv,
Xuewu Liu,
Shengjun Wang
Publication year - 2019
Publication title -
neuropsychiatric disease and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.819
H-Index - 67
eISSN - 1178-2021
pISSN - 1176-6328
DOI - 10.2147/ndt.s222258
Subject(s) - cxcl13 , medicine , chemokine , encephalitis , immunology , biomarker , glioma , immune system , cancer research , virus , chemokine receptor , biology , biochemistry
Although antibody-mediated immune responses are considered pathogenic and responsible for neural injury in anti-leucine-rich glioma-inactivated protein 1 (anti-LGI1) encephalitis, previous studies have indicated that cytokines and chemokines might play roles in the pathogenic process by serving as B cell enhancers. In this study, we detected the profiles of cytokines and chemokines in the cerebral fluid (CSF) and serum of patients with anti-LGI1 encephalitis to identify potential biomarkers.